

### Collusive activities

## CCP issues show-cause notice to Pharma Bureau

Commission of Pakistan (CCP) notice and conducted the inquiry handed over the relevant record ments and decisions on increase issued a show cause notice to the members for prima facie unrea-Pharma Bureau for prima facie sonably increasing the prices of that the Pharma Bureau and its through the platform of Pharma engaging in collusive activities in various medicines through collumembers appear to have been Bureau. It would be pertinent to violation of Section 4 of the sive practices. Competition Act, 2010.

KARACHI: The Competition Commission took a suo motu the inspection team of CCP and pare recommendations, agreehas completed an inquiry and against Pharma Bureau and its to CCP for examination.

Pharma Bureau is the associa- Commission also conducted a information, providing updates associations from taking deci-Multinational search and inspection of the and overview of prices, cost, sions on commercial matters of Pharmaceutical Companies Pharma Bureau early this year profits, demand, and the industry its members such as pricing, pro-(MPCs) and is part of the under Section 34 of the as a whole. The report further duction, and sales etc. As per the Oversees Investors' Chamber of Competition Act during which stated that this information was inquiry report, the sharing of

involved in sharing of strategic mention here that Section 4 of As part of the inquiry, the and commercially sensitive the Act, inter alia, prohibits trade

in prices of various pharmaceuti-

The enquiry report concluded cal products by the companies Commerce and Industry. The the Bureau fully cooperated with used to deliberate upon and pre- above information by Pharma Bureau and its members constitute prima facie violation of Section 4 of the Act.

> It is well-established principle of competition law that not only formal and informal price-fixing agreements, understandings and decisions, but also exchange of commercially sensitive information and setting prices, among other things, between the competitors by themselves or through the medium of their association(s) reduces uncertainty for each of the participant as to the conduct of their competitors. which results in restriction of competition by object and ultimately consumer harm.

> Pharma Bureau has been directed to file a reply to the allegations within fourteen days and has been provided an opportunity of hearing before the Commission.-PR



# Pharma Bureau issued show-cause notice for collusion

By Our Staff Reporter

ISLAMABAD: The Competition Commission of Pakistan (CCP) on Tuesday issued a show-cause notice to Pharma Bureau for prima facie engaging in collusive activities and unreasonably increasing the prices of various medicines.

Pharma Bureau is the association of multinational pharmaceutical companies and is part of the Oversees Investors' Chamber of Commerce and Industry.

The CCP took suo motu notice and conducted the inquiry against Pharma Bureau and its members for prima facie unreasonably increasing the prices of various medicines through collusive practices.

The inquiry report revealed that sharing of information by Pharma Bureau and its members constituted prima facie violation of Section 4 of the Competition Act. As part of the inquiry, the commission also conducted a search and inspection of the Pharma Bureau early this year during which the association fully cooperated with the inspection team of CCP and handed over the relevant record for examination.

The inquiry report concluded that the Pharma Bureau and its members appear to have been involved in sharing of strategic and commercially sensitive information, providing updates and overview of prices, cost, profits, demand, and the industry as a whole.

The report further stated that this information was used to deliberate upon and prepare recommendations, agreements and decisions on increase in prices of various pharmaceutical products by the companies through the platform of Pharma Bureau.

It would be pertinent to mention here that Section 4 of the Act, inter alia, prohibits trade associations from taking decisions on commercial matters of its members such as pricing, production, and sales etc.

It is well-established principle of competition law that not only formal and informal price-fixing agreements, understandings and decisions, but also exchange of commercially sensitive information and setting prices, among other things, between the competitors by themselves or through the medium of their association(s) reduces uncertainty for each of the participant as to the conduct of their competitors, which results in restriction of competition by object and ultimately consumer harm.

INTERNATIONAL

09 November 2016 Back Page

Unreasonable raise in prices of various medicines

### CCP issues show cause notice to Pharma Bureau

#### Mehtab Halder

ISLAMABAD: The Competition Commission of Pakistan I (CCP) has completed an inquiry and issued a show cause notice to the Pharma Bureau for prima facie engaging in collusive activities for unreasonably increasing prices of various medicines.

The show cause notice was issued to them after allegedly committing violation of Section 4 of the Competition Act. 2010.

The Pharma Bureau is the association of Multinational Pharmaceutical Companies (MPCs) and is part of the Oversees Investors' Chamber of Commerce and Industry. The Commission took suo moto notice and conducted the inquiry against Pharma Bureau and its members for prima facie unreasonably increasing the prices of various medicines through collusive practices.

As part of the inquiry, the Commission also conducted a search and inspection of the Pharma Bureau early this year under Section 34 of the Competition Act during which the Bureau fully cooperated with the inspection team of CCP and handed over the relevant record to CCP for examina-

ř

tion. The enquiry report con-cluded that the Pharma Bureau and its members appear to have been involved in sharing of strategic and commercially sensitive information, providing updates and overview of prices, cost, profits, demand, and the industry as a whole. The report further stated that this information was used to deliberate upon and prepare recommendations, agreements and deci-sions on increase in prices of various pharmaceutical products by the companies through the platform of Pharma Bureau.

It would be pertinent to mention here that Section 4 of the Act, inter alia, prohibits trade associations from taking decisions on commercial matters of its members such as pricing, production, and sales etc. As per the inquiry report, the sharing of above information by Pharma Bureau and its members constitute prima facie violation of Section 4 of the Act.

The Nation on Web

## The Nation On November 2016

Page # 08

## CCP issues show-cause notice to Pharma Bureau

## OUR STAFF REPORTER ISLAMABAD

The Competition Commission of Pakistan (CCP) has completed an inquiry and issued a show-cause notice to the Pharma Bureau for prima facie engaging in collusive activities in violation of Section 4 of the Competition Act, 2010.

Pharma Bureau is the association of multinational pharmaceutical companies (MPCs) and is part of the Oversees Investors' Chamber of Commerce and Industry. The Commission took notice and conducted the inquiry against Pharma Bureau and its members for prima facie unreasonably increasing the prices of various medicines through collusive practices.

As part of the inquiry, the Commission also conducted a search and inspection of the Pharma Bureau early this year under Section 34 of the Competition Act during which the Bureau fully cooperated with the inspection team of CCP and handed over the relevant record to CCP for examination.

The enquiry report concluded that the Pharma Bureau and its members appear to have been involved in sharing of strategic and commercially sensitive information, providing updates and overview of prices, cost, profits, demand, and the industry as a whole. The report further stated that this information was used to deliberate upon and prepare recommendations, agreements and decisions on increase in prices of various pharmaceutical products by the companies through the platform of Pharma Bureau.

It would be pertinent to mention here that Section 4 of the Act, inter alia, prohibits trade associations from taking decisions on commercial matters of its members such as pricing, production, and sales etc. As per the inquiry report, the sharing of above information by Pharma Bureau and its members constitute prima facie violation of Section 4 of the Act. It is well-established principle of competition law that not only formal and informal price-fixing agreements, understandings and decisions, but also exchange of commercially sensitive information and setting prices, among other things, between the competitors by themselves or through the medium of their association(s) reduces uncertainty for each of the participant as to the conduct of their competitors, which results in restriction of competition by object and ultimately consumer harm.



09 November 2016

Page # B2

### CCP issues show cause notice to Pharma Bureau

Staff Report

ISLAMABAD: The Competition Commission of Pakistan (CCP) has completed an inquiry and issued a show cause notice to the Pharma Bureau for prima facie engaging in collusive activities in violation of Section 4 of the Competition Act, 2010.

Pharma Bureau is the association of Multinational

Pharma Bureau is the association of Multinational Pharmaceutical Companies (MPCs) and is part of the Oversees Investors' Chamber of Commerce and Industry. The commission took suo motu notice and conducted the inquiry against Pharma Bureau and its members for prima facie unreasonably increasing the prices of various medicines through collu-

sive practices.

As part of the inquiry, the commission also conducted a search and inspection of the bureau earlier this year under Section 34 of the Competition Act during which the bureau fully cooperated with the inspection team of CCP and handed over the relevant record to CCP for examination.

The enquiry report concluded that the Pharma Bureau and its members appear to have been involved in sharing of strategic and commercially sensitive information, providing updates and overview of prices, cost, profits, demand, and the industry as a whole. The report further stated that this information was used to deliberate upon and prepare recommendations, agreements and decisions on increase in prices of various pharmaceutical products by the companies through the platform of Pharma Bureau.

It would be pertinent to mention that section 4 of the act, inter alia, prohibits trade associations from taking decisions on commercial matters of its members such as pricing, production, and sales etc. As per the inquiry report, the sharing of above information by Pharma Bureau and its members constitute prima facie violation of Section 4 of the Act.

## PAKISTAN TODAY

09 November 20165 Page 10

### CCP show causes Pharma Bureau for collusive activities

ISLAMABAD STAFF REPORT

The Competition Commission of Pakistan (CCP) has completed an inquiry and issued a show cause notice to Pharma Bureau for engaging in collusive activities in violation of the Competition Act, and directed it to file a reply to the allegations within fourteen days. The Commission took suo motu notice and conducted the inquiry against Pharma Bureau and its members for prima facie unreasonably increasing the prices of various medicines through collusive practices. Pharma Bureau is an association of multinational pharmaceutical companies and is part of the Oversees Investors' Chamber of Commerce and Industry. As part of the inquiry, the Commission also conducted a search and inspection of Pharma Bureau early this year under Section 34 of the Competition Act during which the Bureau fully cooperated with the inspection team of the CCP and handed over the relevant records for examination. The enquiry report concluded that the Pharma Bureau and its members appear to have been involved in sharing of strategic and commercially sensitive information, providing updates and overview of prices, cost, profits, demand, and the industry as a whole. This information was used to deliberate upon and prepare recommendations, agreements and decisions on increase in prices of various pharmaceutical products by the companies through the platform of Pharma Bureau. It would be pertinent to mention here that Section 4 of the Act, inter alia, prohibits trade associations from taking decisions on commercial matters of its members such as pricing, production, and sales etc. As per the inquiry report, the sharing of above information by Pharma Bureau and its members constitute prima facie violation of Section 4 of the Act. It is a well-established principle of competition law that not only formal and informal price-fixing agreements, understandings and decisions, but also exchange of commercially sensitive information and setting prices, among other things, between the competitors by themselves or through the medium of their association(s) reduces uncertainty for each of the participant as to the conduct of their competitors, which results in restriction of competition by object and ultimately, consumer harm.

# MHT

09 November 2016 Page 7

## CCP issues show cause notice to Pharma Bureau for collusive activities

ISLAMABAD, November 8: The Competition Commission of Pakistan (CCP) on Tuesday completed an inquiry and issued a show cause notice to the Pharma Bureau for prima facie engaging in collusive activities in violation of Section 4 of the Competition Act, 2010.

Pharma Bureau is the association of Multinational Pharmaceutical Companies (MPCs) and is part of the Oversees Investors' Chamber of Commerce and Industry. The Commission took suo motu notice and conducted the inquiry against Pharma Bureau and its members for prima facie unreasonably increasing

the prices of various medicines through collusive practices.

As part of the inquiry, the Commission also conducted a search and inspection of the Pharma Bureau early this year under Section 34 of the Competition Act during which the Bureau fully cooperated with the inspection team of CCP and handed over the relevant record to CCP for examination.

The enquiry report concluded that the Pharma Bureau and its members appear to have been involved in sharing of strategic and commercially sensitive information, providing updates and overview of prices, cost, profits, demand, and the industry as a whole.

The report further stated that this information was used to deliberate upon and prepare recommendations, agreements and decisions on increase in prices of various pharmaceutical products by the companies through the platform of Pharma Bureau.

It would be pertinent to mention here that Section 4 of the Act, inter alia, prohibits trade associations from taking decisions on commercial matters of its members such as pricing, production, and sales etc. -DNA



فار ما بیوروا در ممبرزنے ایسوی ایش کے ذریعے متعدد فار ماسیوٹر کل مصنوعات کے زخ میں اضافے کیلیے قیمتوں، لاگت، منافع سمیت حساس معلومات کا تبادلہ کیا

### فا نونٹریڈالیوی ایشنز کوممنوع معاہدوں ہےرو کتا ہے،مسابقتی کمیشن،ازخودنوٹس کی انگوائزی مکمل، فار ما بیورو ہے 14 دن کےاندرنوٹس کا جواب طلب

اركث عن سابقت يراثر اتداز موت موع عام صارف کے لیے نقصان کا باعث بن سکتا ہے۔ی ی لی نے فار مایورو کوشوکاز نوش جاری کرتے ہوے 14 ون

كاندرجواب داخل كرنے كى بدايت كى ب-

ا قانون كے يشن 4 ك تحت كيش ثريد ايسوى ايشز كوا يے ارْخُودنونس ليت ہوئے الكوائرى كى ،اس دوران كيش نے منوع معاہدوں سے روکتا ہےجن سے قیمتیں، بداوار اور فروخت متاثر مواور حربف كاروبارى ادارول كوآلي

میں حاس معلومات کے تباد لے مجی منع کرتا ہے جو

سابقتی قانون کے سیشن 34 کے تحت عاصل کردہ اختارات کواستعال میں لاتے ہوئے کھے عرصة لل فارما ا بورو کے وفتر کی سرچ اینڈ اسکشن بھی کی، اس ممل کے ووران فارما بورو نے لیشن کی سرج ٹیم کے ساتھ ملل تعاون کیا اور متعلقہ ریکارڈ جانچ پر تال کے لیے ی کی لی كحوالي كا الكوائرى عظامر مواكد فارما يوروك ممران آپس من قيتول من اتار چنهاؤ، طلب، منافع

چیبر آف کامرس اینڈ انڈسٹریز کا حصہ ب، مسابقتی اور حساس تجارتی معلومات بانٹنے میں ملوث تھے اور فار با سیونکل کمپنیزان معلومات کوفار ما بیورو کے پلیٹ فارم کے

ذریع مخلف ادویہ کی قیمتوں میں اضافہ کرنے کے

معابدے اور فیصلوں میں استعال کرتی تھیں، سابقتی

اسلام آباد (خصوصی ربورش) مسابقی میشن آف

یا کتان (ی ی بی) نے سابقی قوانین کی خلاف ورزی پر قارما بورو کوشوکاز نوٹس جاری کردیا ہے۔ گزشتہ روز جاری اعلاہے کے مطابق ی کی نے اکواڑی کے بعد

قار ما بيوروكو يادى التظريس ساز بازيس ملوث موت اور سابقتی ایک کے سیشن فورکی خلاف ورزی پرشوکا زلوش

جاری کیا ہے۔ اعلامے کے مطابق قارما بورومٹی عشل فارما سيونكل كمينز رمشمل ايسوى ايش ب جوادوريز

میش آف یا کتان نے فار ما بورواوراس کے مبران كے خلاف مخلف ادور كى قيتوں ميں بادى النظر ميں ساز

باز کے ذریع غیر معقول اضافے میں ملوث ہوتے پر



## ی پی نے فار مابیور وکوساز باز میں ملوث ہونے پر شوکا زنوٹس جاری کر دیا

## ممبران آپس میں قیمتوں میں اتار چڑھاؤ،طلب،منافع اور حساس تجارتی معلومات با منے میں ملوث تھے

جانج يوتال كے لئے ى كى في كے حوالے كيا۔اكوائرى ے ظاہر ہوا کہ فار ما بورو کے ممبران آپس میں قیتوں میں اتار جرهاؤ،طلب،منافع اور حیاس تجارتی معلومات بانتن ميس ملوث تضاور فارماسيوركل كمينيزان معلومات کو فار ما بیورو کے پلیٹ فارم کے ذریعے مختلف ادویات کی قیمتوں میں اضافیہ کرنے کے معاہدے اور فیملوں میں استعال کرتے تھے میٹیشن ایک کے سیشن 4 کر تحت کمیشن ٹریڈ ایسوی ایشنز کو ایسے ممنوعہ معاہدول سے روکتا ہے جن سے بیمتیں، پیداوار اور فروخت متاثر موراور حريف كاروبارى ادارول كوآلي میں حناس معلومات کے تباد لے سے بھی منع کرتا ہے جو کہ مارکیٹ میں میٹیشن پراٹر انداز ہوتے ہوئے عام صارف کے لیے نقصان کا باعث بن سکتا ہے۔ی ی لی نے فار مایوروکوشوکازنونس جاری کرتے ہوے14 ون کے اندراک شوکا زنونس کا جواب دینے کا کہاہے۔

البلام آباد (نمائنده خصوصی)مپیٹیشن کمیشن آف یا کشان نے انگوائری کے بعد فار ما بیوروکو بادی النظر میں ساز باز میں ملوث ہونے اور میٹیشن ایک کے سیشن 4 کی خلاف ورزی پر شوکاز نوٹس حاری کر دیا ہے۔فاریا بوروملی پیشل فار ماسیونکل کمپنیز پرمشمل ایسوی ایش ہے وكة اووريز جيلر آف كاعرك النشائد يزكا حد ہے۔ سینیشن لیمشن آف یا کستان نے فار ما بیورو اوراس کے ممبران کے خلاف مختلف ادویات کی قیمتوں میں بادی النظريس ساز باز كے زريع غير معقول اضافے ميں ملوث ہونے پر ازخو دنوٹس لیتے ہوئے انکوائری کی۔ انکوائری کے دوران کمیشن نے میٹیشن ایکٹ کے سیکشن 34 کے تحت حاصل کردواختیارات کواستعال میں لاتے ہوئے کچھ عرصہ قبل فارما بیورو کے دفتر کی سرچ اینڈ اسپشن بھی کی اوراس ممل کے دوران فار ما بیورو نے کمیشن کی سرچ ٹیم کے ساتھ ململ تعاون کیا اور متعلقہ ریکارڈ



کامرس رپورٹر )مسابقتی نے انکوائری کے بعد فار ما بیوروکو یا دی النظ ملوث ہونے اور مسابقتی ایکٹ کے کی خلاف ورزی پرشو کازنونس حاری کر دیا ہے۔فار ما جو کہ او درسیز چیمیر آ ف کا مرس اینڈ انڈسٹر پڑ کا ثن آف ماکتان نے فارما بیورو اور اس مختلف ادویات کی قیمتوں میں یادی کے زریعے غیرمعقول اضافے میں ملور ، پرازخودنونس لیتے ہوئے انگوائری کی۔



# مرابقی کمیشن کے فارما پیورو کوچی کارٹوئش جاری کردیا

كراجي (كامرس ريورز) سابقتي كميش آف یا کتان (ی ی بی) نے انگوائری کے بعد فار ما بیوروکو بادی انظر میں ساز باز میں ملوث ہونے اور سابقتی ا یک کے عیشن 4 کی خلاف ورزی پرشوکا زنونس جاری کر دیا ہے۔فارما بیورومکی نیشنل فارما سیوٹیکل کمپنیز پر مشمل ایسوی ایش ب جو که او در بیز چیبر آف کامری ابند اندسريز كاحسب-مابقتي كميش آف ياكتان نے فارما بورو اور اس کے ممبران کے خلاف مختلف ادوبات کی قیتوں میں بادی النظر میں ساز باز کے زریعے غیرمعقول اضافے میں ملوث ہونے پر از خو و نوس کتے ہوئے انگوائری کی۔ Kir Best. 14



## سی می پی نے فار ماہیور وکوساز باز میں ملوث ہونے پرشو کا زنوٹس جاری کرویا

اسلام آباد (نامه نگار خصوصی) میشن آف پاکتان نے انکوائری کے بعد فار ما بیوروکو بادی انظر میں ساز باز میں ملوث ہونے اور میپیشن ایکٹ کے سیشن 4 کی خلاف ورزی پرشوکاز نولس جاری کردیا ہے۔ فار ما بیورو ملٹی میشنل فار ما سیونکل میشیز پر مشتمل ایسوسی ایشن ہے جو کہ اوور سیز چیمبر آف کامرس اینڈ انڈسٹر پز کا حصہ ہے۔ میپیشن کمیشن آف پاکستان نے فار ما بیورواوراس کے ممبران کے خلاف مختلف اوویات کی قیمتوں میں بادی انظر میں ساز باز کے (باقی صفحہ 7 بقیہ نمبر 54)

اکوائری الخیم الزخود الفاف بین ملوث ہونے پر ازخود النے بین ملوث ہونے پر ازخود نوس کیے موت ہونے پر ازخود نوس کیے ہوئے الکوائری کی۔ اکوائری کے دوران کیشن نے سینیشن ایک کے تحت ماصل کردہ اختیارات کواشتمال بین لاتے ہوئے پرکھ مرص جل فار ما بیورو کے دفتر کی سرچ اینڈ اسپلشن بھی کی اوراس ممل کے دوران فار ما بیورو نے کیشن کی سرچ اینڈ اسپلشن کی سرچ اینڈ اسپلسن کی سرچ اینڈ جانچ پڑ تال کے ساتھ ممل تعاون کیا ادر متعلقہ ریکارڈ جانچ پڑ تال کے لئے سی کی کے والے کیا۔





09 November 2016 Page 6

ہونے برازخودتولس لیتے ہوئے انگوائری کی انگوائری کے دوران کمیش نے سابقتی ایک کے سیشن 34 کے تحت حاصل کردہ اختیارات کو استعال میں لاتے ہوئے کھ عرصة لل فار ما بيورو كے دفتر كى س چ اينڈ انسيكش بھى كى اور اس عمل کے دوران فار ما بورو نے کمیشن کی سرچ فیم کے ساتھ مکمل تعاون کیا اور متعلقہ ریکارڈ جانچ پڑتال کے لیے ى ى لى كرحوالي كيا الكوائرى عظامر مواكه فارمايورو ا کے ممبران آپس میں قیمتوں میں اتار چڑھاؤ، طلب، منافع اورحياس تحارتي معلومات بانتخ مين ملوث تقے اور فارما سیوٹکا کمپنیز ان معلوبات کو فار ما بیورو کے بلیٹ فارم کے معاہدے اور فیصلوں میں استعال کرتی تھیں۔ ی کی لی نے مے میران کے خلاف مختلف ادو یہ کی تیتوں میں یادی النظر افار ماہیور وکوشو کازنوٹس جاری کرتے ہوئے 14 دن کے میں سازیاز کے ذریعے غیر معقول اضافے میں ملوث الدراس شوکازنوش کا جواب دینے کا کہا ہے۔

# ی میشن نے فار ماہور وکو شوكازنونس حارى كروبا

كراجي (آن لائن) ما بقتي كيش آف باكتان (ى ى لى) نے الكوائرى كے بعد فار ما بيوروكو بادى النظر میں سازیاز میں ملوث ہونے اورمسابقتی ایکٹ کے پیشن 4 کی خلاف ورزی برشو کازنوش جاری کرویا ہے۔فار ما بور ملی مشل فار ما سیونکل کمینیز رمشمل ایسوی ایش ہے جو کہ ادور سیز چیبر آف کامن اینڈ انڈسٹریز کا حصہ ازریع مختلف ادویہ کی قیتوں میں اضافہ کرنے کے ے۔سابقتی کیش آف یا کتان نے فارما بورد اور اس